Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Summit Corporation plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Summit Corporation plc - Product Pipeline Review - 2014', provides an overview of the Summit Corporation plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Summit Corporation plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Summit Corporation plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Summit Corporation plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Summit Corporation plc's pipeline products Reasons to buy - Evaluate Summit Corporation plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Summit Corporation plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Summit Corporation plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Summit Corporation plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Summit Corporation plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Summit Corporation plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Summit Corporation plc Snapshot 5 Summit Corporation plc Overview 5 Key Information 5 Key Facts 5 Summit Corporation plc - Research and Development Overview 6 Key Therapeutic Areas 6 Summit Corporation plc - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Summit Corporation plc - Pipeline Products Glance 13 Summit Corporation plc - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Summit Corporation plc - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Summit Corporation plc - Drug Profiles 17 SMT-19969 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 SMTC-1100 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Seglin O-linked N-acetylglucosaminidase Inhibitors 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 SMT-14224 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 SMT-15000 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SMT-21829 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 SMTC-2100 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Next Generation Utrophin Modulator 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Inhibit NS3 Helicase for Hepatitis C 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecules to Modulate Utrophin for Duchenne Muscular Dystrophy 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Summit Corporation plc - Pipeline Analysis 28 Summit Corporation plc - Pipeline Products by Target 28 Summit Corporation plc - Pipeline Products by Route of Administration 29 Summit Corporation plc - Pipeline Products by Molecule Type 30 Summit Corporation plc - Pipeline Products by Mechanism of Action 31 Summit Corporation plc - Recent Pipeline Updates 32 Summit Corporation plc - Dormant Projects 39 Summit Corporation plc - Discontinued Pipeline Products 40 Discontinued Pipeline Product Profiles 40 SMTD-001 40 Summit Corporation plc - Locations And Subsidiaries 41 Head Office 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 43 Disclaimer 43
List of Tables Summit Corporation plc, Key Information 5 Summit Corporation plc, Key Facts 5 Summit Corporation plc - Pipeline by Indication, 2014 8 Summit Corporation plc - Pipeline by Stage of Development, 2014 9 Summit Corporation plc - Monotherapy Products in Pipeline, 2014 10 Summit Corporation plc - Out-Licensed Products in Pipeline, 2014 11 Summit Corporation plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Summit Corporation plc - Phase II, 2014 13 Summit Corporation plc - Phase I, 2014 14 Summit Corporation plc - Preclinical, 2014 15 Summit Corporation plc - Discovery, 2014 16 Summit Corporation plc - Pipeline by Target, 2014 28 Summit Corporation plc - Pipeline by Route of Administration, 2014 29 Summit Corporation plc - Pipeline by Molecule Type, 2014 30 Summit Corporation plc - Pipeline Products by Mechanism of Action, 2014 31 Summit Corporation plc - Recent Pipeline Updates, 2014 32 Summit Corporation plc - Dormant Developmental Projects,2014 39 Summit Corporation plc - Discontinued Pipeline Products, 2014 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.